Ravi Retnakaran, MD, FRCPC, is a distinguished Professor in the Department of Medicine, Division of Endocrinology and Metabolism at the University of Toronto. His research program is dedicated to investigating the pathophysiology and treatment of type 2 diabetes (T2DM), with a particular focus on the potential reversibility of pancreatic beta-cell dysfunction in early diabetes. His research group is conducting innovative clinical trials, including the CIHR-funded RESET IT Trial and PREVAIL Trial, to evaluate novel therapeutic strategies for preserving beta-cell function in early T2DM. Additionally, Dr. Retnakaran's research has revealed valuable insights into the gluco-regulatory response of women during pregnancy, providing unique perspectives into their future risk of T2DM and cardiovascular disease. This concept is under study through prospective observational cohorts in Toronto and China, funded by CIHR. His contributions significantly advance our understanding of diabetes and open new avenues for its management and prevention.